A client receiving teprotumumab for thyroid eye disease returns before the next infusion. Highlight the findings that require prompt medication follow-up.
Highlight in Table
Choose your responses, then check the answer.
Explanation
Marked hyperglycemia, new persistent tinnitus or hearing decline, bloody diarrhea with cramping, and an infusion-related hypotensive rash are important teprotumumab safety signals.
Quick answer Escalate glucose, hearing, bowel, and infusion toxicities.
Why this is correct Teprotumumab can worsen glycemia, cause severe and sometimes permanent hearing impairment, exacerbate or reveal inflammatory bowel disease, and trigger infusion reactions.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: TEPEZZA (teprotumumab)Hyperglycemia, inflammatory bowel disease, severe or permanent hearing impairment, and infusion reactions
Oncology, transplant, and biologic safety reviewVerify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.